MedTrace Logo

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 717

Last updated 2025-07-18

No results posted yet for this study

Summary

The primary objectives of the study are:

* To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time.
* To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities

The secondary objectives of the study are:

* To characterize real-world utilization of DUPIXENT® for patients with CRSwNP
* To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP
* To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Conditions

  • Chronic Rhinosinusitis With Nasal Polyposis

Interventions

DRUG

DUPIXENT®

No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2027-03-25
Completion
2027-03-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Italy
  • Japan
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04959448 on ClinicalTrials.gov